Growth and Cell Cycle Abnormalities of Fibroblasts From Tangier Disease Patients
- 1 January 1999
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 19 (1) , 28-38
- https://doi.org/10.1161/01.atv.19.1.28
Abstract
—We have investigated the abnormal proliferation and morphology of fibroblasts from patients with Tangier disease (TD), a high density lipoprotein (HDL) deficiency syndrome that is characterized by impairment of HDL3-mediated lipid efflux and Gi-protein–mediated signaling via phosphatidylinositol-specific phospholipase C (PI-PLC) and phospholipase D (PLD). TD fibroblasts displayed a 30% to 50% reduced in vitro growth rate and a 1.6-fold increased cell surface area. The response to different mitogens was diminished, and asynchronously growing TD fibroblasts showed 4.4±0.3% S-phase and 19.1±0.5% G2/M-phase cells compared with 9.7±0.6% and 7.8±0.5%, respectively, in controls. Monensin, but not brefeldin A, induced an S- and G2/M-phase distribution in control cells similar to that found in TD fibroblasts. This effect of monensin was accompanied by an increase of ceramide levels in controls, whereas TD fibroblasts already had a 2.5-fold increased basal ceramide concentration. Incubation of control cells with C2 ceramide andthreo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) mimicked the effect of monensin on the cell cycle. The inhibition of neither Giprotein function by pertussis toxin nor PLD by butanol resulted in a G2/M-phase arrest. Propranolol, known to increase phosphatidic acid levels, was ineffective in reversing the G2/M-phase arrest in TD fibroblasts. In addition, cDNA sequences and mRNA expression of the participants of PI-PLC or PLD signaling, ie, G-protein subunits αi1, αi2, and αi3; phosphatidylinositol transfer proteins-α and -β; and ADP ribosylation factors 1 and 3 were found to be normal. Thus, growth and cell cycle abnormalities in TD fibroblasts are likely to be related to impaired Golgi function and sphingolipid signaling rather than inoperative G-protein signal transduction. Because PDMP was also found to decrease HDL3-mediated lipid efflux in control but not TD fibroblasts, similar pathways seem to be involved in the disturbances of lipid transport and growth retardation.Keywords
This publication has 46 references indexed in Scilit:
- Involvement of pertussis toxin‐sensitive GTP‐binding proteins in sphingosine 1‐phosphate‐induced activation of phospholipase CCa2+ system in HL60 leukemia cellsFEBS Letters, 1996
- Cloning and expression of human cDNA encoding phosphatidylinositol transfer protein βBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1995
- A role for phosphatidylinositol transfer protein in secretory vesicle formationNature, 1995
- Phosphatidylinositol transfer protein dictates the rate of inositol trisphosphate production by promoting the synthesis of PIP2Current Biology, 1995
- Sequence of a human cDNA encoding phosphatidylinositol transfer protein and occurrence of a related sequence in widely divergent eukaryotesGene, 1994
- A role for phospholipase D in control of mitoqenesisTrends in Pharmacological Sciences, 1994
- Brefeldin A: insights into the control of membrane traffic and organelle structure.The Journal of cell biology, 1992
- Alteration of intracellular traffic by monensin; mechanism, specificity and relationship to toxicityBiochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, 1990
- In vivo metabolism of proapolipoprotein A-I in Tangier disease.Journal of Clinical Investigation, 1987
- Apoprotein A-I Synthesis in Normal Intestinal Mucosa and in Tangier DiseaseNew England Journal of Medicine, 1978